Trials / Unknown
UnknownNCT02224443
Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients
Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients-A Single Center,Randomized, Double-blinded,Controlled Study
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University · Academic / Other
- Sex
- All
- Age
- 65 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to identify the effects of different doses of dexmedetomidine on postoperative cognitive dysfunction in elderly hypertensive patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexmedetomidine | Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation |
| DRUG | dexmedetomidine | Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation |
| DRUG | normal saline | Group C , Normal saline infusion will be given with the same infusion volume as group A and B |
| DRUG | midazolam,fentanyl,etomidate,Cisatracurium besylate | Anesthesia induction : 0.05 mg.kg-1 midazolam,4\~5μg.kg-1 fentanyl,1.0\~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate |
| DRUG | cisatracurium besylate,propofol,remifentanil,sevoflurane | Maintenance of anesthesia :Continuous pump infusion 0.05\~0.1mg.kg-1.h-1cisatracurium besylate,4\~8mg.kg-1.h-1propofol,0.1\~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%\~1.0% |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2015-08-01
- Completion
- 2015-09-01
- First posted
- 2014-08-25
- Last updated
- 2014-08-25
Source: ClinicalTrials.gov record NCT02224443. Inclusion in this directory is not an endorsement.